Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21152328 | 0.82 | NOTUM (0.72) | LMNANOTUMTP53SMN1; SMN2KMT2A | |
| SCHEMBL16523816 | 0.79 | MAPT (0.63) | LMNANOTUMKMT2AMAPT | |
| SCHEMBL1960697 | 0.77 | MAPT (0.61) | LMNANOTUMTP53SMN1; SMN2KMT2A | |
| SCHEMBL3389730 | 0.77 | NOTUM (0.63) | LMNANOTUMTP53SMN1; SMN2KMT2A | |
| SCHEMBL29556202 | 0.77 | MAPT (0.61) | LMNANOTUMTP53SMN1; SMN2KMT2A | |
| SCHEMBL30016360 | 0.77 | KEAP1 (0.63) | NOTUM | |
| SCHEMBL29134867 | 0.77 | KEAP1 (0.63) | NOTUM | |
| SCHEMBL4583569 | 0.75 | TP53 (0.70) | LMNANOTUMTP53SMN1; SMN2KMT2A | |
| SCHEMBL4809224 | 0.74 | LMNA (0.73) | LMNANOTUMTP53SMN1; SMN2KMT2A | |
| SCHEMBL16551211 | 0.74 | LMNA (0.73) | LMNANOTUMTP53SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | LMNA 2855/4885NOTUM 3763/4885TP53 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.